*
*
Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable
54321NA
The skills learned in this CME course enhanced my professional competence.
The skills learned in this CME course will be applied in the treatment of my patients.
*
5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence NA|Not applicable to my practice
54321
Implement updates on T cell-engaging therapies for myeloma?
Treat AL amyloidosis?
Assess myelodysplastic syndrome (MDS) and who to transplant and who not to transplant?
Treat intestinal microbiome in cancer immunotherapy?
*
Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied NA=Not Applicable
54321NA
Next Steps in CAR T-Cell Therapies - Michel Sadelain, M.D., Ph.D.
Optimizing CAR T-Cell Homing via GPS- Robert Sackstein, M.D.
Do CARs Always Have to be T-Cells- Paul Lin, M.D.
Myelodysplastic Syndrome (MDS): Who to Transplat and Who Not to Transplant- Wael Saber, M.D.
Novel Insights in the Development of Acute GVHD- Alan Hanash, M.D.
Novel Approaches to GVHD Prevention and Therapy- Corey Cutler, M.D.
Donor and Graft Source Optimization for Allo Transplant- Robert Soiffer, M.D.
Redifining Preventation - What’s Next for GVHD Prophalaxis?- Leo Luznik, M.D.
Is it time for post-transplant Maintenance Therapies in AML?- Guenther Koehne, M.D.
*
*
*
*
*
*
*
*